End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
4.43 CNY | -3.49% | -7.90% | -22.28% |
Jun. 03 | China Grants Marketing Approval for Ampicillin Sodium as Active Pharmaceutical Ingredient | MT |
May. 24 | North China Pharmaceutical's Unit Passes GMP Inspection | MT |
Sales 2022 | 10.5B 1.45B | Sales 2023 | 10.12B 1.4B | Capitalization | 9.78B 1.35B |
---|---|---|---|---|---|
Net income 2022 | -689M -95.11M | Net income 2023 | 4M 552K | EV / Sales 2022 | 1.94 x |
Net Debt 2022 | 9.37B 1.29B | Net Debt 2023 | 10.16B 1.4B | EV / Sales 2023 | 1.97 x |
P/E ratio 2022 |
-15.9
x | P/E ratio 2023 |
1,900
x | Employees | 10,159 |
Yield 2022 * |
-
| Yield 2023 |
0.18% | Free-Float | 41.8% |
1 day | -3.49% | ||
1 week | -7.90% | ||
Current month | -7.52% | ||
1 month | -14.48% | ||
3 months | -8.28% | ||
6 months | -29.91% | ||
Current year | -22.28% |
Managers | Title | Age | Since |
---|---|---|---|
Xin Yan Liu
CEO | Chief Executive Officer | 54 | 18-08-27 |
Jian Jun Li
DFI | Director of Finance/CFO | 53 | 09-08-31 |
Suo Qing Zhang
BRD | Director/Board Member | 54 | 20-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Guang Cheng Pan
BRD | Director/Board Member | 75 | 19-05-21 |
De Min Zhou
BRD | Director/Board Member | 58 | 19-05-21 |
Ji Gang Xie
BRD | Director/Board Member | 51 | 21-04-22 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +4.23% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-06 | 4.43 | -3.49% | 12,964,780 |
24-06-05 | 4.59 | -1.29% | 8,033,300 |
24-06-04 | 4.65 | 0.00% | 7,184,700 |
24-06-03 | 4.65 | -2.92% | 11,530,070 |
24-05-31 | 4.79 | 0.00% | 6,593,800 |
End-of-day quote Shanghai S.E., June 05, 2024
More quotes1st Jan change | Capi. | |
---|---|---|
-22.28% | 1.09B | |
+43.64% | 749B | |
+39.42% | 605B | |
-6.58% | 351B | |
+19.72% | 328B | |
+8.78% | 292B | |
+11.92% | 216B | |
-2.62% | 214B | |
+0.03% | 167B | |
+6.13% | 165B |
- Stock Market
- Equities
- 600812 Stock